These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 15497754)
41. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Huo D; Deng S; Li L; Ji J Int J Pharm; 2005 Jan; 289(1-2):63-7. PubMed ID: 15652199 [TBL] [Abstract][Full Text] [Related]
42. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes. Sun W; Zhang N; Li A; Zou W; Xu W Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370 [TBL] [Abstract][Full Text] [Related]
43. Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. Yao J; Zhou JP; Ping QN; Lu Y; Chen L Int J Pharm; 2008 Mar; 352(1-2):256-62. PubMed ID: 18053660 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. Li S; Wang A; Jiang W; Guan Z BMC Cancer; 2008 Apr; 8():103. PubMed ID: 18412945 [TBL] [Abstract][Full Text] [Related]
45. Preparation and characterization of 5-fluorouracil pH-sensitive niosome and its tumor-targeted evaluation: in vitro and in vivo. Wang M; Yuan Y; Gao Y; Ma HM; Xu HT; Zhang XN; Pan WS Drug Dev Ind Pharm; 2012 Sep; 38(9):1134-41. PubMed ID: 22182601 [TBL] [Abstract][Full Text] [Related]
46. [Effects of intravenous alimentation on adjuvant chemotherapy--an experimental study on the distribution of 5-FU after injection of tegafur (2)]. Kimoto M; Nagano H; Sano K Gan To Kagaku Ryoho; 1987 Oct; 14(10):2859-64. PubMed ID: 3116943 [TBL] [Abstract][Full Text] [Related]
47. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Menei P; Boisdron-Celle M; Croué A; Guy G; Benoit JP Neurosurgery; 1996 Jul; 39(1):117-23; discussion 123-4. PubMed ID: 8805147 [TBL] [Abstract][Full Text] [Related]
48. Kidney- and site-selective delivery of 5-fluorouracil utilizing the absorption on the kidney surface in rats. Kawakami S; Horimoto T; Nishida K; Hirayama R; Mukai T; Nakashima M; Sasaki H; Sakaeda T; Nakamura J Biol Pharm Bull; 2002 Jul; 25(7):928-30. PubMed ID: 12132672 [TBL] [Abstract][Full Text] [Related]
49. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. Innocenti F; Danesi R; Bocci G; Natale G; Del Tacca M Toxicol Appl Pharmacol; 2005 Mar; 203(2):106-13. PubMed ID: 15710171 [TBL] [Abstract][Full Text] [Related]
50. Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers. Fournier E; Passirani C; Colin N; Breton P; Sagodira S; Benoit JP Eur J Pharm Biopharm; 2004 Mar; 57(2):189-97. PubMed ID: 15018974 [TBL] [Abstract][Full Text] [Related]
51. New formulation of 5-fluorouracil in microspheres reduces toxicity in mice. Hagiwara A; Sakakura C; Tsujimoto H; Ohgaki M; Imanishi T; Yamazaki J; Sawai K; Takahashi T; Yamamoto A; Muranishi S; Tabata Y; Ikada Y Anticancer Drugs; 1996 Sep; 7(7):780-4. PubMed ID: 8949990 [TBL] [Abstract][Full Text] [Related]
52. HPLC method for the pharmacokinetics and tissue distribution of taspine solution and taspine liposome after intravenous administrations to mice. Lu W; He LC; Zeng XM J Pharm Biomed Anal; 2008 Jan; 46(1):170-6. PubMed ID: 17889477 [TBL] [Abstract][Full Text] [Related]
53. Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration. Yang YW; Lee JS; Kim I; Jung YJ; Kim YM Eur J Pharm Biopharm; 2007 May; 66(2):260-7. PubMed ID: 17182232 [TBL] [Abstract][Full Text] [Related]
54. Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model. Shishu ; Kamalpreet ; Maheshwari M Drug Dev Ind Pharm; 2012 Mar; 38(3):294-300. PubMed ID: 21864111 [TBL] [Abstract][Full Text] [Related]
55. In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil. Chen W; Wu Z; Yang H; Guo S; Li D; Cheng L Pharm Dev Technol; 2014 Mar; 19(2):223-31. PubMed ID: 23432601 [TBL] [Abstract][Full Text] [Related]
56. Absorption and distribution characteristics of 5-fluorouracil (5-FU) after an application to the liver surface in rats in order to reduce systemic side effects. Kodama Y; Fumoto S; Nishi J; Nakashima M; Sasaki H; Nakamura J; Nishida K Biol Pharm Bull; 2008 May; 31(5):1049-52. PubMed ID: 18451546 [TBL] [Abstract][Full Text] [Related]
57. Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. Seto Y; Takenoue T; Nariko H; Kaminishi M Cancer; 2000 Jun; 88(11):2443-6. PubMed ID: 10861418 [TBL] [Abstract][Full Text] [Related]
58. [Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice]. Huo MR; Zhou JP; Wei Y; Lü L Yao Xue Xue Bao; 2006 Sep; 41(9):867-72. PubMed ID: 17111835 [TBL] [Abstract][Full Text] [Related]
59. Dendrimer grafts for delivery of 5-fluorouracil. Tripathi PK; Khopade AJ; Nagaich S; Shrivastava S; Jain S; Jain NK Pharmazie; 2002 Apr; 57(4):261-4. PubMed ID: 11998447 [TBL] [Abstract][Full Text] [Related]
60. Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors. Sun W; Chen Y; Yuan W Int J Nanomedicine; 2013; 8():1499-506. PubMed ID: 23626465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]